NASDAQ:TNYA Tenaya Therapeutics Q3 2025 Earnings Results & Report $0.38 -0.03 (-6.78%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$0.38 +0.00 (+0.87%) As of 10/16/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tenaya Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$0.12 versus the -$0.15 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeBefore Market OpensConference Call7:00 AM ET Tenaya Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS -$0.15Beat/MissBeat by +$0.03One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersTenaya Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTenaya Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Tenaya Therapeutics Q3 2025 Earnings FAQ Did Tenaya Therapeutics beat earnings estimates for Q3 2025? Tenaya Therapeutics (NASDAQ:TNYA) reported earnings of -$0.12 per share for Q3 2025, beating the consensus estimate of -$0.15. The report was announced on Monday, November 10, 2025. When is Tenaya Therapeutics' next earnings date? Tenaya Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Tenaya Therapeutics on the company's earnings history page. Tenaya Therapeutics Earnings HeadlinesTenaya Therapeutics (NASDAQ:TNYA) and Sutro Biopharma (NASDAQ:STRO) Critical ContrastOctober 13, 2026 | americanbankingnews.comTenaya Therapeutics Announces RMAT Designation To TN-401September 14, 2026 | rttnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)Tenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock UpSeptember 14, 2026 | rttnews.comTenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...September 14, 2026 | finance.yahoo.comTenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathySeptember 14, 2026 | globenewswire.comSee More Tenaya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email. Email Address About Tenaya TherapeuticsTenaya Therapeutics (NASDAQ:TNYA) (NASDAQ:TNYA) is a biotechnology company focused on developing therapies for cardiovascular diseases. The company uses a combination of gene therapy, cell therapy, and precision medicine approaches to address the genetic and biological causes of heart disease, including conditions for which treatment options remain limited. Tenaya’s research and development programs have included therapies designed to replace or correct disease-associated genes and restore the function of cardiac muscle cells. Its pipeline has included TN-201, an investigational gene therapy for hypertrophic cardiomyopathy associated with MYBPC3 mutations, and TN-401, an investigational gene therapy being developed for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 mutations. The company has also pursued discovery programs involving gene editing, induced pluripotent stem cell-derived cardiomyocytes, and small-molecule medicines. Founded in 2016 and headquartered in South San Francisco, California, Tenaya conducts research and development activities primarily in the United States while seeking to advance potential treatments for patients with inherited and other serious cardiovascular disorders. The company is led by Chief Executive Officer Faraz Ali.View Tenaya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
